Ascento-CDA
Early detection analytics mapping biologic activity in dementia and diabetes to reduce costs and cre
Company Overview
Snapshot
Founded in December 2024 by Marvin Collin, Rami Cohen, and Raphael Nir, Ascento-CDA operates with 1–10 employees. The company has raised $350,000 across one funding round. In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline, showcasing its analytical capabilities.
Business overview
Ascento-CDA is a healthcare analytics company developing a scalable platform for the early detection of dementia and diabetes. Its proprietary analytic engine integrates immunology data, retinal imaging signals, and cognitive assessments to identify early biologic activity that conventional tools often miss. The platform serves insurers, payers, and health providers by enabling earlier, more targeted interventions to reduce lifetime medical costs and unlock new revenue streams through diagnostics and pre-clinical care programs. Ascento-CDA operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Decision Support, leveraging Artificial Intelligence and Machine Learning.
Strategic signal
In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline. This publication validates the company's core technology and its potential to significantly impact the early detection of neurodegenerative diseases, signaling to investors a strong scientific foundation and a clear path toward clinical application and market differentiation.
Log in to access full profile ›Company Intelligence Q&A
- When was Ascento-CDA founded?
- Ascento-CDA was founded in December 2024.
- Who are the founders of Ascento-CDA?
- Ascento-CDA was founded by Marvin Collin, Rami Cohen, and Raphael Nir.
- What is Ascento-CDA's primary focus?
- Ascento-CDA focuses on early detection analytics for dementia and diabetes, aiming to identify biologic activity before symptoms appear to reduce healthcare costs and improve patient outcomes.
- What significant research did Ascento-CDA publish?
- In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline using inflammatory, immunologic, and cognitive mapping (IICM™).
- What is Ascento-CDA's total disclosed funding?
- Ascento-CDA has raised a total of $350,000 across one Seed funding round in January 2025.